{"protocolSection": {"identificationModule": {"nctId": "NCT00577655", "orgStudyIdInfo": {"id": "IXR-302-25-105"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Albuterol HFA MDI in Pediatric Participants With Asthma", "officialTitle": "Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-08"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-18", "studyFirstSubmitQcDate": "2007-12-19", "studyFirstPostDateStruct": {"date": "2007-12-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-07-21", "resultsFirstSubmitQcDate": "2009-10-27", "resultsFirstPostDateStruct": {"date": "2009-12-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-11-11", "lastUpdatePostDateStruct": {"date": "2021-11-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Pediatric, asthma, albuterol-HFA and Placebo"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 103, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Albuterol", "type": "EXPERIMENTAL", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.", "interventionNames": ["Drug: Albuterol", "Drug: Proventil\u00ae HFA"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as \"Placebo-HFA-MDI.\")", "interventionNames": ["Drug: Placebo", "Drug: Proventil\u00ae HFA"]}], "interventions": [{"type": "DRUG", "name": "Albuterol", "description": "Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.", "armGroupLabels": ["Albuterol"], "otherNames": ["ProAir\u00ae HFA", "Albuterol Sulfate"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo HFA MDI four times a day (q.i.d) for 21 days.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Proventil\u00ae HFA", "description": "Proventil\u00ae HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.", "armGroupLabels": ["Albuterol", "Placebo"], "otherNames": ["albuterol sulfate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "timeFrame": "35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing on Day 22 or last observation"}, {"measure": "Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) Observed up to Two Hours Post Dose (PEFmax%0-2) on Day 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "timeFrame": "30\u00b15 and 5\u00b12 minutes prior to dosing, and at 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing on Day 22 or last observation"}], "secondaryOutcomes": [{"measure": "Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) up to Two Hours Post-Dose (FEV1max%0-2, %) on Study Days 1 and 22 Using Observed Cases", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using test day baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing"}, {"measure": "Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) up to Two Hours Post-Dose (PEFmax%0-2) on Study Days 1 and 22 Using Observed Cases", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing on study days 1 and 22. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "timeFrame": "Days 1 and 22: 30\u00b15 and 5\u00b12 minutes prior to dosing, and 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing"}, {"measure": "Baseline Adjusted Area-under-the-Effect Curve for Percent of Predicted Forced Expiratory Volume in One Second (FEV1) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.\n\nThe area under-the-effect curves for percent-predicted FEV1 were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.", "timeFrame": "Baseline (Day 1 or Day 22: 35\u00b15 and 10\u00b12 minutes prior to dosing), Day 22 (5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120\u00b110, 240\u00b110, and 360\u00b110 minutes post-dosing or last observation)"}, {"measure": "Baseline-Adjusted Area-under-the Effect Curve for Peak Expiratory Flow (PEF) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nThe area under-the-effect curves for PEF were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.", "timeFrame": "Baseline (Day 1 or Day 22: 30\u00b15 and 5\u00b12 minutes prior to dosing Day 22: 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing or last observation"}, {"measure": "Maximum Percent-Predicted FEV1 (Max PPFEV1, %) Observed up to Two Hours Following Completion of Dosing on Study Days 1 and 22 (Observed Case)", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.", "timeFrame": "Days 1 and 22: 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing"}, {"measure": "Time To Maximum Forced Expiratory Volume in One Second (FEV1) Over Six Hours Post-Dose On Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters.\n\nTime to maximum FEV1 is defined as the number of minutes required for the baseline FEV1 to increase to the highest FEV1 post dose during the 6 hour observation period.\n\nMedian time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing"}, {"measure": "Time To Maximum Peak Expiratory Flow (PEF) Over Six Hours Post-Dose On Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nTime to maximum PEF is defined as the number of minutes required for the baseline PEF to increase to the highest PEF post-dose for the 6 hour observation period. Median time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.", "timeFrame": "Days 1 and 22: 30\u00b15 and 5\u00b12 minutes prior to dosing, and 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing"}, {"measure": "Participant Responses: Percentage of Participants With a >=15% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing"}, {"measure": "Participant Responses: Percentage of Participants With a >=12% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing"}, {"measure": "Participant Responses: Percentage of Participants With a >=15% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing"}, {"measure": "Participant Responses: Percentage of Participants With a >=12% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing"}, {"measure": "Weekly Average Highest (Worst) Daily Asthma Symptom Scores for Weeks 1, 2 and 3", "description": "Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms were scored daily on a four-point scale:\n\n* 0 = No symptoms occurred\n* 1 = Symptom occurred but did not interfere with daily activity\n* 2 = Symptom occurred but was sometimes annoying or interfered with daily activity\n* 3 = Symptom present even at rest and was annoying or interfered with daily activity", "timeFrame": "Weeks 1, 2, 3"}, {"measure": "The Number of Asthma-Related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.", "timeFrame": "Run-in (Days -21 to -1), Weeks 1, 2, 3"}, {"measure": "Weekly Average Peak Expiratory Flow (PEF) Obtained Pre-Dose Each Morning", "description": "Participants measured their PEF as trained by taking as deep a breath as possible, placing their mouth firmly around the mouthpiece of the flow meter to form a tight seal, and exhaling as hard and as fast as possible. Subjects repeated the process twice at intervals of approximately 30 seconds, and then recorded the highest of the three PEF values on the diary card.", "timeFrame": "Weeks 1, 2, 3"}, {"measure": "Weekly Average Number of Puffs of Rescue Medication Taken Each Day for Study Weeks 1, 2 and 3", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night and the number of puffs of rescue albuterol used during the night after going to bed. At the end of each day, the number of puffs of albuterol rescue medication used during the day were recorded.", "timeFrame": "Weeks 1, 2, 3"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female child aged 4-11 years, inclusive Asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening.\n\nExclusion Criteria:\n\n* Hospitalization for acute asthma exacerbation greater than two years in 12 months prior to screening and/or received ER treatment or hospitalization for asthma exacerbation.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Study Physician MD", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pediatric Care Medical Group, Inc.", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "California Allergy & Asthma Medical Group", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Center for Clinical Trials, LLC", "city": "Paramount", "state": "California", "zip": "90723", "country": "United States", "geoPoint": {"lat": 33.88946, "lon": -118.15979}}, {"facility": "Integrated Research Group, Inc", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Center for Clinical Trials of Sacramento", "city": "Sacramento", "state": "California", "zip": "95823", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Carlos Piniella, MD", "city": "Miami", "state": "Florida", "zip": "33157", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Sneeze, Wheeze & Itch Associates, Inc.", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Asthma & Allergy Associates, PC", "city": "Elmira", "state": "New York", "zip": "14901", "country": "United States", "geoPoint": {"lat": 42.0898, "lon": -76.80773}}, {"facility": "ENT & Allergy Associates", "city": "Newburgh", "state": "New York", "zip": "12550", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "St. Elizabeth's Children Health Center", "city": "Utica", "state": "New York", "zip": "13502", "country": "United States", "geoPoint": {"lat": 43.1009, "lon": -75.23266}}, {"facility": "Regional Allergy & Asthma Consultants", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Clinical Research Institute of Southern Oregan, PC", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Virginia Adult & Pediatric Allergy & Asthma", "city": "Richmond", "state": "Virginia", "zip": "23229", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "208 individual subjects were screened; ten subjects failed the initial screening but were later re-screened and successfully enrolled.", "groups": [{"id": "FG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "FG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "This number represents the number of participants randomized.", "numSubjects": "52"}, {"groupId": "FG001", "comment": "This number represents the number of participants randomized.", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "47"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Patient Request", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "BG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "103"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "1.82"}, {"groupId": "BG001", "value": "8.2", "spread": "2.09"}, {"groupId": "BG002", "value": "8.2", "spread": "1.95"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "39"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "69"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "North American Indian or Alaska native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "103"}]}]}]}, {"title": "Forced Expiratory Volume in One Second (FEV1) on Day 1", "description": "Baseline measurement is the average of two Day 1 pre-dose FEV1 values. n=51, 51, 103", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.52", "spread": "0.38"}, {"groupId": "BG001", "value": "1.49", "spread": "0.46"}, {"groupId": "BG002", "value": "1.50", "spread": "0.42"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "populationDescription": "Intent-To-Treat (ITT) population with Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change from baseline", "timeFrame": "35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing on Day 22 or last observation", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo-HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.849", "spread": "1.005"}, {"groupId": "OG001", "value": "9.353", "spread": "1.017"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Efficacy was declared if the test for either primary efficacy endpoint was significant at the 0.025 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0138", "pValueComment": "In order to control the overall alpha level at the 0.05 value, each of the primary endpoints were tested separately at the 0.025 level of significance.", "statisticalMethod": "ANCOVA", "statisticalComment": "Baseline as covariate and fixed effects of treatment and pooled investigator site.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.496", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.729", "ciUpperLimit": "6.262", "estimateComment": "Active - Placebo"}]}, {"type": "PRIMARY", "title": "Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) Observed up to Two Hours Post Dose (PEFmax%0-2) on Day 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "populationDescription": "Intent-To-Treat (ITT) population with Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change from baseline", "timeFrame": "30\u00b15 and 5\u00b12 minutes prior to dosing, and at 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing on Day 22 or last observation", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo-HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.558", "spread": "1.878"}, {"groupId": "OG001", "value": "12.127", "spread": "1.907"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Efficacy was declared if the test for either primary efficacy endpoint was significant at the 0.025 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0403", "pValueComment": "In order to control the overall alpha level at the 0.05 value, each of the primary endpoints were tested separately at the 0.025 level of significance.", "statisticalMethod": "ANCOVA", "statisticalComment": "Baseline as covariate and fixed effects of treatment and pooled investigator site.", "paramType": "Mean Difference (Final Values)", "paramValue": "5.431", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.244", "ciUpperLimit": "10.618", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) up to Two Hours Post-Dose (FEV1max%0-2, %) on Study Days 1 and 22 Using Observed Cases", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using test day baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "populationDescription": "Observed cases (i.e. available data only)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change from baseline", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo-HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.621", "spread": "1.072"}, {"groupId": "OG001", "value": "8.085", "spread": "1.075"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.601", "spread": "1.072"}, {"groupId": "OG001", "value": "9.534", "spread": "1.119"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1\n\nA repeated measures mixed model, with terms for treatment, pooled center, study day, treatment by study day interaction, and baseline as a covariate, and subject as a random term, was used to make comparisons between placebo and active with respect to FEV1max%0-2 at Days 1 and 22, with observed case data.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0031", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "4.536", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.567", "ciUpperLimit": "7.505", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22\n\nA repeated measures mixed model, with terms for treatment, pooled center, study day, treatment by study day interaction, and baseline as a covariate, and subject as a random term, was used to make comparisons between placebo and active with respect to FEV1max%0-2 at Days 1 and 22, with observed case data.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0470", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "3.067", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.041", "ciUpperLimit": "6.094", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) up to Two Hours Post-Dose (PEFmax%0-2) on Study Days 1 and 22 Using Observed Cases", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (\u00b12 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing on study days 1 and 22. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.", "populationDescription": "Observed cases", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change from baseline", "timeFrame": "Days 1 and 22: 30\u00b15 and 5\u00b12 minutes prior to dosing, and 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo-HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.040", "spread": "1.982"}, {"groupId": "OG001", "value": "12.468", "spread": "2.004"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.776", "spread": "1.997"}, {"groupId": "OG001", "value": "12.994", "spread": "2.076"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1\n\nA repeated measures mixed model, with terms for treatment, pooled center, study day, treatment by study day interaction, and baseline as a covariate, and subject as a random term, was used to make comparisons between placebo and active with respect to PEFmax%0-2 at Days 1 and 22, with observed case data.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0074", "pValueComment": "significance level of 0.05.", "statisticalMethod": "repeated measures ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "7.572", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.077", "ciUpperLimit": "13.067", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22\n\nA repeated measures mixed model, with terms for treatment, pooled center, study day, treatment by study day interaction, and baseline as a covariate, and subject as a random term, was used to make comparisons between placebo and active with respect to PEFmax%0-2 at Days 1 and 22, with observed case data.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1843", "pValueComment": "significance level of 0.05.", "statisticalMethod": "repeated measures ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "3.782", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.832", "ciUpperLimit": "9.397", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Baseline Adjusted Area-under-the-Effect Curve for Percent of Predicted Forced Expiratory Volume in One Second (FEV1) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.\n\nThe area under-the-effect curves for percent-predicted FEV1 were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.", "populationDescription": "Intent-To-Treat (ITT) population with Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent of Predicted FEV1 * Hours", "timeFrame": "Baseline (Day 1 or Day 22: 35\u00b15 and 10\u00b12 minutes prior to dosing), Day 22 (5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120\u00b110, 240\u00b110, and 360\u00b110 minutes post-dosing or last observation)", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 22 Baseline (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.046", "spread": "3.531"}, {"groupId": "OG001", "value": "21.338", "spread": "3.588"}]}]}, {"title": "Day 1 Baseline (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.060", "spread": "6.748"}, {"groupId": "OG001", "value": "24.167", "spread": "6.773"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22 Baseline", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0507", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment and center, baseline as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "9.707", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.030", "ciUpperLimit": "19.445", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1 Baseline", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.9240", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANOVA", "statisticalComment": "terms for treatment and center", "paramType": "Mean Difference (Final Values)", "paramValue": "0.892", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.634", "ciUpperLimit": "19.419", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Baseline-Adjusted Area-under-the Effect Curve for Peak Expiratory Flow (PEF) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nThe area under-the-effect curves for PEF were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.", "populationDescription": "Intent-To-Treat (ITT) population with Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/Minute*Hours", "timeFrame": "Baseline (Day 1 or Day 22: 30\u00b15 and 5\u00b12 minutes prior to dosing Day 22: 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing or last observation", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 22 Baseline (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "120.82", "spread": "17.486"}, {"groupId": "OG001", "value": "90.693", "spread": "17.753"}]}]}, {"title": "Day 1 Baseline (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "139.42", "spread": "25.782"}, {"groupId": "OG001", "value": "96.842", "spread": "26.117"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22 Baseline", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.2186", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment and center, baseline as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "30.124", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.169", "ciUpperLimit": "78.417", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1 Baseline", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.2375", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment and center, baseline as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "42.578", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.541", "ciUpperLimit": "113.70", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Maximum Percent-Predicted FEV1 (Max PPFEV1, %) Observed up to Two Hours Following Completion of Dosing on Study Days 1 and 22 (Observed Case)", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.", "populationDescription": "Observed cases (i.e. available data only)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "Days 1 and 22: 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo-HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.898", "spread": "1.451"}, {"groupId": "OG001", "value": "89.374", "spread": "1.462"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "94.650", "spread": "1.451"}, {"groupId": "OG001", "value": "90.652", "spread": "1.488"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0017", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANOVA", "statisticalComment": "terms for treatment, center, time, time x treatment, subject as a random", "paramType": "Mean Difference (Final Values)", "paramValue": "6.524", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.524", "ciUpperLimit": "10.523", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0521", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANOVA", "statisticalComment": "terms for treatment, center, time, time x treatment, subject as a random", "paramType": "Mean Difference (Final Values)", "paramValue": "3.998", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.037", "ciUpperLimit": "8.032", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Time To Maximum Forced Expiratory Volume in One Second (FEV1) Over Six Hours Post-Dose On Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters.\n\nTime to maximum FEV1 is defined as the number of minutes required for the baseline FEV1 to increase to the highest FEV1 post dose during the 6 hour observation period.\n\nMedian time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.", "populationDescription": "Intent-To-Treat (ITT) population; Last Observation Carried Forward (LOCF) used for Day 22", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "minutes", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15, 45\u00b15, 60\u00b110, 120 \u00b110 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.95", "lowerLimit": "32.03", "upperLimit": "51.73"}, {"groupId": "OG001", "value": "45.25", "lowerLimit": "30.32", "upperLimit": "62.82"}]}]}, {"title": "Day 22 with LOCF (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.54", "lowerLimit": "29.55", "upperLimit": "45.67"}, {"groupId": "OG001", "value": "61.05", "lowerLimit": "46.53", "upperLimit": "120.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0647", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "1.477", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.98", "ciUpperLimit": "2.23", "estimateComment": "Active/Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0005", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "2.088", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.38", "ciUpperLimit": "3.15", "estimateComment": "Active/Placebo"}]}, {"type": "SECONDARY", "title": "Time To Maximum Peak Expiratory Flow (PEF) Over Six Hours Post-Dose On Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nTime to maximum PEF is defined as the number of minutes required for the baseline PEF to increase to the highest PEF post-dose for the 6 hour observation period. Median time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.", "populationDescription": "ITT population; Last Observation Carried Forward (LOCF) used for Day 22", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "minutes", "timeFrame": "Days 1 and 22: 30\u00b15 and 5\u00b12 minutes prior to dosing, and 7.5\u00b12, 20\u00b15, 35\u00b15, 50\u00b15, 65\u00b110, 125\u00b110 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.50", "lowerLimit": "34", "upperLimit": "64"}, {"groupId": "OG001", "value": "35.00", "lowerLimit": "33", "upperLimit": "65"}]}]}, {"title": "Day 22 with LOCF (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.5", "lowerLimit": "22", "upperLimit": "50"}, {"groupId": "OG001", "value": "63.00", "lowerLimit": "35", "upperLimit": "115"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.5059", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "1.141", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "1.69", "estimateComment": "Active/Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0333", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "1.533", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.03", "ciUpperLimit": "2.27", "estimateComment": "Active/Placebo"}]}, {"type": "SECONDARY", "title": "Participant Responses: Percentage of Participants With a >=15% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "populationDescription": "ITT", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.6"}, {"groupId": "OG001", "value": "9.8"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.6"}, {"groupId": "OG001", "value": "6.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.3888", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1249", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Participant Responses: Percentage of Participants With a >=12% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.", "populationDescription": "ITT", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=51, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "13.7"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.4"}, {"groupId": "OG001", "value": "14.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0343", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0962", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Participant Responses: Percentage of Participants With a >=15% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.", "populationDescription": "ITT", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.2"}, {"groupId": "OG001", "value": "19.6"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.2"}, {"groupId": "OG001", "value": "23.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0109", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0845", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Participant Responses: Percentage of Participants With a >=12% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22", "description": "The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.", "populationDescription": "ITT", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Days 1 and 22: 35\u00b15 and 10\u00b12 min prior to dosing, and at 5\u00b12, 15\u00b15, 30\u00b15 post dosing", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Day 1 (n=52, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.7"}, {"groupId": "OG001", "value": "25.5"}]}]}, {"title": "Day 22 (n=51, 47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.9"}, {"groupId": "OG001", "value": "29.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Day 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0013", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Day 22", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0085", "pValueComment": "significance level of 0.05.", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Weekly Average Highest (Worst) Daily Asthma Symptom Scores for Weeks 1, 2 and 3", "description": "Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms were scored daily on a four-point scale:\n\n* 0 = No symptoms occurred\n* 1 = Symptom occurred but did not interfere with daily activity\n* 2 = Symptom occurred but was sometimes annoying or interfered with daily activity\n* 3 = Symptom present even at rest and was annoying or interfered with daily activity", "populationDescription": "ITT population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 1, 2, 3", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Week 1 (N=50, N=50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.370", "spread": "0.070"}, {"groupId": "OG001", "value": "0.442", "spread": "0.070"}]}]}, {"title": "Week 2 (N=50, N=49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.376", "spread": "0.070"}, {"groupId": "OG001", "value": "0.547", "spread": "0.071"}]}]}, {"title": "Week 3 (N=47, N=48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.336", "spread": "0.072"}, {"groupId": "OG001", "value": "0.474", "spread": "0.071"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4674", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as a covariate, subject as random.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.072", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.265", "ciUpperLimit": "0.122", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0840", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as covariate, subject as random", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.171", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.365", "ciUpperLimit": "0.023", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 3", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1699", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as covariate, subject as random", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.138", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.335", "ciUpperLimit": "0.059", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "The Number of Asthma-Related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "awakenings/week", "timeFrame": "Run-in (Days -21 to -1), Weeks 1, 2, 3", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Run-In (N=52, N=51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.15", "spread": "2.97"}, {"groupId": "OG001", "value": "1.06", "spread": "2.44"}]}]}, {"title": "Week 1 (N=51, N=50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.14", "spread": "3.25"}, {"groupId": "OG001", "value": "1.00", "spread": "2.84"}]}]}, {"title": "Week 2 (N=51, N=49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.16", "spread": "3.82"}, {"groupId": "OG001", "value": "0.73", "spread": "1.97"}]}]}, {"title": "Week 3 (N=49, N=48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "2.21"}, {"groupId": "OG001", "value": "1.33", "spread": "3.13"}]}]}]}, {"type": "SECONDARY", "title": "Weekly Average Peak Expiratory Flow (PEF) Obtained Pre-Dose Each Morning", "description": "Participants measured their PEF as trained by taking as deep a breath as possible, placing their mouth firmly around the mouthpiece of the flow meter to form a tight seal, and exhaling as hard and as fast as possible. Subjects repeated the process twice at intervals of approximately 30 seconds, and then recorded the highest of the three PEF values on the diary card.", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/minute", "timeFrame": "Weeks 1, 2, 3", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Week 1 (N=51, N=50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "229.65", "spread": "4.800"}, {"groupId": "OG001", "value": "219.72", "spread": "4.854"}]}]}, {"title": "Week 2 (N=51, N=49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "229.90", "spread": "4.800"}, {"groupId": "OG001", "value": "218.97", "spread": "4.870"}]}]}, {"title": "Week 3 (N=49, N=48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "231.28", "spread": "4.820"}, {"groupId": "OG001", "value": "221.73", "spread": "4.880"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1391", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as a covariate, subject as random.", "paramType": "Mean Difference (Final Values)", "paramValue": "9.926", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.256", "ciUpperLimit": "23.108", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1043", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as a covariate, subject as random.", "paramType": "Mean Difference (Final Values)", "paramValue": "10.923", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.278", "ciUpperLimit": "24.124", "estimateComment": "Active - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 3", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1570", "pValueComment": "significance level of 0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "terms for treatment, center, week, week by treatment, baseline as a covariate, subject as random.", "paramType": "Mean Difference (Final Values)", "paramValue": "9.546", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.705", "ciUpperLimit": "22.798", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Average Number of Puffs of Rescue Medication Taken Each Day for Study Weeks 1, 2 and 3", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night and the number of puffs of rescue albuterol used during the night after going to bed. At the end of each day, the number of puffs of albuterol rescue medication used during the day were recorded.", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of puffs per day", "timeFrame": "Weeks 1, 2, 3", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "Week 1 (N=51, N=50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.074", "lowerLimit": "0.009", "upperLimit": "0.138"}, {"groupId": "OG001", "value": "0.075", "lowerLimit": "0.011", "upperLimit": "0.139"}]}]}, {"title": "Week 2 (N=51, N=49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.084", "lowerLimit": "0.011", "upperLimit": "0.158"}, {"groupId": "OG001", "value": "0.088", "lowerLimit": "0.013", "upperLimit": "0.163"}]}]}, {"title": "Week 3 (N=49, N=48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.078", "lowerLimit": "0.010", "upperLimit": "0.146"}, {"groupId": "OG001", "value": "0.088", "lowerLimit": "0.013", "upperLimit": "0.163"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 1\n\nP-value, mean and confidence interval calculated from a 0 inflated mixed poisson regression model with fixed effect terms for treatment, week, treatment by week interaction, baseline as a covariate and a random term for subject. The null hypothesis is that the ratio equals 1. Estimated means are conditional upon the random effect, assume a random effect of 0 and a covariate value at the average.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.9846", "pValueComment": "significance level of 0.05.", "statisticalMethod": "mixed poisson regression model", "paramType": "ratio of Active to Placebo", "paramValue": "0.989", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.121", "ciUpperLimit": "2.099"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2\n\nP-value, mean and confidence interval calculated from a 0 inflated mixed poisson regression model with fixed effect terms for treatment, week, treatment by week interaction, baseline as a covariate and a random term for subject. The null hypothesis is that the ratio equals 1. Estimated means are conditional upon the random effect, assume a random effect of 0 and a covariate value at the average.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.9447", "pValueComment": "significance level of 0.05.", "statisticalMethod": "mixed poisson regression model", "paramType": "ratio of Active to Placebo", "paramValue": "0.961", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.116", "ciUpperLimit": "2.039"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 3\n\nP-value, mean and confidence interval calculated from a 0 inflated mixed poisson regression model with fixed effect terms for treatment, week, treatment by week interaction, baseline as a covariate and a random term for subject. The null hypothesis is that the ratio equals 1. Estimated means are conditional upon the random effect, assume a random effect of 0 and a covariate value at the average.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8326", "pValueComment": "significance level of 0.05.", "statisticalMethod": "mixed poisson regression model", "paramType": "ratio of Active to Placebo", "paramValue": "0.887", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.111", "ciUpperLimit": "1.885"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Days 1-22", "eventGroups": [{"id": "EG000", "title": "Albuterol", "description": "Albuterol-HFA-MDI 180 mcg, four times a day", "seriousNumAffected": 0, "seriousNumAtRisk": 52, "otherNumAffected": 7, "otherNumAtRisk": 52}, {"id": "EG001", "title": "Placebo", "description": "Placebo HFA-MDI four times a day for 21 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 5, "otherNumAtRisk": 51}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 52}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 52}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 51}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If review shows that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for up to 90 additional days to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure of multicenter data, but not longer than 12 months from study completion/termination at all participating sites."}, "pointOfContact": {"title": "Teva Study Physician", "organization": "Teval Global Respiratory Research LLC", "phone": "215-293-6482"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}